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Abstract: Mammalian peroxiredoxin class 6 (Prdx6) are bifunctional enzymes. Non-mammalian
Prdx6 enzymes display Cys-based peroxidase activity, but to date their putative phospholipase
A2 (PLA2 activities) has not been experimentally investigated. Initially, we observed that five
non-mammalian Prdx6 enzymes (enzymes from Arabidopsis thaliana (AtPER1), Triticum aestivum
(TaPER1), Pseudomonas aeruginosa (PaLsfA) and Aspergillus fumigatus (AfPrx1 and AfPrxC)) present
features compatible with PLA2 activities in mammalian Prdx6 by amino acid sequences alignment
and tertiary structure modeling. Employing unilamellar liposomes with tracer amounts of
[3H]-1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and thin layer chromatography, all the
tested non-mammalian Prdx6 enzymes displayed PLA2 activities, with values ranging from 3.4 to
6.1 nmol/min/mg protein. It was previously shown that Thr177 phosphorylation of human Prdx6
increases its PLA2 activity, especially at neutral pH. Therefore, we investigated if human Erk2 kinase
could also phosphorylate homologous Thr residues in non-mammalian Prdx6 proteins. We observed
phosphorylation of the conserved Thr in three out of the five non-mammalian Prdx enzymes by mass
spectrometry. In the case of the mitochondrial Prdx6 from A. fumigatus (AfPrxC), we also observed
phosphorylation by western blot, and as a consequence, the PLA2 activity was increased in acidic
and neutral conditions by the human Erk2 kinase treatment. The possible physiological meanings of
these PLA2 activities described open new fields for future research.
Keywords: Peroxiredoxin; Prdx6; PLA2 activity; 1-Cys Prdx
1. Introduction
Peroxiredoxins (Prdxs) are ubiquitous enzymes that play prominent roles in regulating peroxide
levels within cells. These enzymes are often abundant and are capable of rapidly reducing peroxides [1].
Prdxs are Cys-based peroxidases that contain one or two conserved Cys residues [2]. To date,
all characterized Prdxs display the universal motif PxxxT/SxxC and can reduce hydroperoxides
efficiently, with rates ranging from 106 to 108 M−1 s−1 [3]. In spite of being a heterogeneous family,
all Prdxs have this peroxidase activity dependent on Thr(Ser)-Cys-Arg catalytic triad that stabilizes the
transition state of the reaction [4].
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According to the PeroxiRedoxin classification index (PREX) database, Prdxs can be classified into
six subfamilies: AhpC/Prx1, Prdx6, Prx5, Tpx, bacterioferritin comigratory protein (BCP)/PrxQ and
AhpE, considering sequence and structural characteristics [5]. The Prdx6 subfamily is widespread
from Eubacteria and Archaea to higher eukaryotes. It comprises almost exclusively 1-Cys Prdx
mechanisms (only one Cys takes part in the catalytic cycle) and forms obligatory antiparallel dimers,
and eventually, higher oligomeric states like decamers (pentamer of dimers). The peroxidase activity
motif PVCTTE (Pro-Val-Cys-Thr-Thr-Glu) comprises the peroxidatic Cys (CysP) and is characteristic of
Prdx6 enzymes [6].
In addition to the peroxidase activity, mammalian Prdx6 displays a Ca2+-independent
phospholipase A2 (aiPLA2) activity [7–9]. The PLA2 comprise a large family of lipolytic enzymes that
hydrolyze the sn-2 acyl bond of phospholipids, releasing a free fatty acid and lysophospholipid [10].
The active sites of the peroxidase and aiPLA2 activities are spatially and functionally independent and
the catalytic triad for human PLA2 activity is composed of the His26, Ser32 and Asp140 residues [11].
The identification of Ser32 residue in the GxSxG motif [7] as the site of phospholipid hydrolysis
involved the use of serine protease inhibitors (e.g., MJ33, 1-hexadecyl-3-trifluoro-ethylglycero-sn-2-
phosphomethanol), structural analyses and site-direct mutagenesis [12]. Afterwards, the lysosomal
targeting signal peptide (GDSWGILFSHP) was determined and it also contains the catalytic Ser
(Ser32) [13]. Notably, mutation of Ser32 to Thr abolished targeting human Prdx6 to lysosome-like
structures while maintaining its PLA2 activity [14].
This aiPLA2 activity is maximum at pH 4, consistent with the subcellular localization of Prdx6
in a lysosome-like organelle. The phosphorylation of Prdx6 at Thr177 by MAP kinase induces a
marked increase in PLA2 activity at acid and neutral pH, indicating that the PLA2 activity may also be
important in the cytosolic environment [15].
The aiPLA2 activity is classically involved in pulmonary surfactant metabolism and membrane
remodeling [16]. More recently, the Prdx6 PLA2 activity was also related to NADPH (Nicotinamide
Adenine Dinucleotide Phosphate) oxidase 2 (NOX2) activation [17,18], and also with the metastasis
and invasiveness of lung cancer cells [19].
So far, PLA2 activity has been identified only in mammalian Prdx6 enzymes. However, Prdx6
enzymes from other taxa also present structural similarities, suggesting that these enzymes might also
possess PLA2 activity. Indeed, among 126 Prdx6 sequences analyzed in a previous study, 67% of the
sequences had the lipase motif (38% had the classic lipase motif GxSxG, 11% had the alternative lipase
motif GxSxA and 18% had variant lipase motifs) [6]. Therefore, we selected 5 non-mammalian Prdx6
enzymes to evaluate their putative PLA2 activity:
1. TaPER1 from Triticum aestivum: its gene is present as a single copy in the plant genome and is
expressed mainly in the cytoplasm and nucleus during the development and germination of
wheat seeds [20].
2. AtPER1 from Arabidopsis thaliana: its gene is also a single copy and its expression is induced
by abscisic acid and oxidative stress [21]. AtPER1 also presents nuclear and cytoplasm
localization [22]. Although knockout mutants for this gene are viable (unpublished data),
overexpression or down-regulation of the AtPER1 gene affect seed germination during abiotic
stresses [23].
3. AfPrx1 from Aspergillus fumigatus is a cytosolic protein that displays high reactivity for H2O2
(k = 2.28 × 107 M−1 s−1) [24]. Moreover, the AfPrx1 is essential for the decomposition of
exogenously added H2O2 as shown by the investigation of a knockout strain (∆afprx1) [25].
The strain ∆afprx1 is also more sensitive to other stressors’ molecules. Additionally, AfPrx1 plays
a role in fungus virulence in neutropenic murine models [24].
4. AfPrxC from Aspergillus fumigatus is a mitochondrial protein that also reacts rapidly with H2O2
(k = 2.28 × 107 M−1 s−1) [24].
Antioxidants 2019, 8, 52 3 of 17
5. PaLsfA from Pseudomonas aeruginosa: PaLsfA is the only 1-Cys Prdx among several antioxidant
proteins in P. aeruginosa. PaLsfA expression is induced upon sulfate depletion [26] and it is
involved with P. aeruginosa virulence [27].
2. Materials and Methods
2.1. Sequence and Structural Analysis
All the Prdx6 sequences studied here were obtained from the National Center for Biotechnology
Information (NCBI) (https://www.ncbi.nlm.nih.gov/) and confirmed in other curated databases:
Phytozome (https://phytozome.jgi.doe.gov) for TaPER1 and AtPER1; AspGD (http://www.aspgd.
org) for AfPrx1 and AfPrxC; and Pseudomonas Genome DB (http://www.pseudomonas.com) for
PaLsfA. The alignment was performed using Clustal Omega program (https://www.ebi.ac.uk/Tools/
msa/clustalo/) [28], and the software Jalview (University of Dundee, Scotland, UK) [29] was used
for visualization.
The structures of non-mammalian Prdx6 were modeled using the human Prdx6 (1PRX) as the
template and the SWISS-MODEL tool (https://swissmodel.expasy.org/) [30]. The UCSF (University of
California, San Francisco) Chimera program [31] was used to visualize and generate the images. The
web based application WebLogo version 2.8.2 (http://weblogo.berkeley.edu, University of California,
Berkeley, USA) was used to generate the lysosomal target sequence logo [32].
2.2. Cloning, Expression and Purification of Recombinant Proteins
The genes of the corresponding Prdxs were cloned in expression vectors as follows: pET16b/
taper1 (kindly provided by Javier Cejudo) and pET15b/atper1; pET15b/palsfA. To clone into pET
expression vectors (Novagen, Madison, USA), the sequences were amplified by polymerase chain
reaction (PCR), from TOPO™ vector (Invitrogen, Carlsbad, USA) containing each sequence, using
the following primers: TaPER1: 5′-ATCATATGCCGGGCCTCACCATCGG-3′ and 5′-ATCTCGAG
CTAGACCTTGGTGAAGCG-3′, which contained sites for NdeI and XhoI restriction enzymes (bold
letters). AtPER1: 5′-ATCATATGCCAGGGATCACACTAGG-3′ and 5′-ATGGATCCTCAAGAGACC
TCTGTGTGACG-3′, which contained sites for NdeI and BamHI restriction enzymes (bold letters).
PaLsfA: 5′-CGCATCATATGCTCAGACTCGGCGAC-3′ and 5′-ACGGATCCTCAGCGGTTGGGC
TG-3′, which contained sites for NdeI and BamHI restriction enzymes (bold letters).
The genes afprx1 and afprxC were codon optimized for Escherichia coli expression and were
synthesized by GenScript® (Piscataway, USA). These genes were then cloned into the NdeI (5’) and
BamHI (3’) restriction sites of the pET15b plasmid. All constructions were confirmed by sequencing,
using T7 promoter and terminator oligonucleotides (BigDyeTM Terminator v3.1 Cycle Sequencing Kit,
Applied Biosystems®, Foster City, USA).
2.2.1. Expression Procedures
Single colonies of E. coli BL21 (DE3) harboring the respective plasmid (pET16b/taper1,
pET15b/atper1, pET15b/afprx1, pET15b/afprxC, pET15b/palsfA) were cultured in Lysogeny broth
medium (LB) containing 100 µg/mL ampicillin and grown for 16 h (37 ◦C) in an orbital shaker
(250 rpm). The cultures were then diluted in 1 L of LB (100 µg/mL ampicillin) and were incubated at
37 ◦C until the optical density OD600nm attained 0.6–0.8 values. Isopropyl β-D-1-thiogalactopyranoside
(IPTG) was then added at a final concentration of 0.3 mM for AfPrx1, AfPrxC and 1 mM for AtPER1 and
TaPER1. Then, each culture was incubated at 37 ◦C for an additional 3 h (250 rpm), with the exception
of PaLsfA, in which 1 mM IPTG was added and the culture incubated at 30 ◦C for 6 h (250 rpm).
Cells were harvested by centrifugation, and the pellet was washed and resuspended in the start buffer
(20 mM sodium phosphate pH 7.4; 500 mM NaCl; 20 mM imidazole; 625 µM phenylmethylsulfonyl
fluoride (PMSF). Twenty cycles of 15 s of sonication (30% amplitude) following 40 s in ice were applied
to cell suspensions. Cell extracts were kept on ice during treatment with 1% streptomycin sulfate for
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15 min and the suspension was centrifuged at 15,000 rpm for 45 min to remove nucleic acid precipitates
and the insoluble fraction.
2.2.2. Purification
Cell extracts were filtered and purified by immobilized metal ion affinity chromatography (IMAC)
using the HisTrap™ FF 5 mL column (GE Healthcare, Chicago, USA), using the ÄKTAFPLC system
(GE Healthcare, Chicago, USA). The conditions of protein purification were optimized using the
gradient procedure for imidazole concentration as described by the manufacturer. Imidazole was
removed from purified proteins by gel filtration using a PD10 column (GE Healthcare, Chicago, US).
Purified proteins were stored in the following buffers: AtPER1 and TaPER1 in 20 mM Tris HCl buffer
(pH 7.4) containing 500 mM NaCl, AfPrx1 and AfPrxC in 20 mM sodium phosphate buffer (pH 7.4)
containing 500 mM NaCl, and PaLsfA in 20 mM HEPES buffer (pH 7.4) containing 150 mM NaCl
and 0.1 mM diethylenetriaminepentaacetic acid (DTPA). Recombinant protein concentrations were
determined spectrophotometrically at 280 nm. The extinction coefficients for reduced AtPER1 (ε280nm
= 24,013 M−1 cm−1), TaPER1 (ε280nm = 21,555 M−1 cm−1), AfPrx1 (ε280nm = 20,970 M−1 cm−1), AfPrxC
(ε280nm = 22,460 M−1 cm−1) and PaLsfA (ε280nm = 33,920 M−1 cm−1) were determined using the
ProtParam tool (http://www.expasy.ch/tools/protparam.html, Lausanne, Switzerland).
2.3. Preparation of Unilamellar Liposomes
The lipids used to make the unilamellar liposomes were: 1,2-Dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) (Sigma-Aldrich P0763, Taufkirchen, Germany); L-α-Phosphatidylcholine
(PC) (Sigma-Aldrich P2772, Taufkirchen, Germany); L-α-Phosphatidyl-DL-glycerol ammonium salt
(PG) (Sigma-Aldrich P0514, Taufkirchen, Germany); cholesterol (Sigma-Aldrich C8667, Taufkirchen,
Germany). The stock solutions were made by diluting the lipids in chloroform.
Unilamellar liposomes were made using DPPC/PC/PG/cholesterol (5:2.5:1:1.5) with tracer
amounts of [3H] DPPC (American Radiolabeled Chemicals ART 0532, Saint Louis, USA). The lipid
solution was evaporated to dryness under N2 and resuspended in isotonic saline. In some cases,
the PLA2 inhibitor MJ33 was added (200 µM). The solution was repeatedly frozen/thawed by
alternating liquid N2 and warm H2O (50 ◦C) (3 times), and then extruded at 50 ◦C for 10 cycles
through a 200 µm pore size membrane to generate unilamellar liposomes using LIPEX™ (Transferra
Nanosciences Inc., Burnaby, Canada). The liposomes were freshly prepared for every use and stored
for short times at 4 ◦C [16].
2.4. Evaluation of PLA2 Activity
The PLA2 activities were determined using unilamellar liposomes (100 µL), containing tracer
amounts of [3H] DPPC. Reaction mixtures contained non-mammalian Prdx6 enzymes (5, 10 or 50 µM)
in an acid (40 mM sodium acetate pH 4, 5 mM ethylenediaminetetraacetic acid (EDTA)) or neutral pH
buffer (50 mM Tris-Cl pH 7.4, 1 mM ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid
(EGTA)), both incubated for 1 h at 37 ◦C. The reactions were interrupted by the addition of 3.75 mL of
chloroform/methanol (1:2) for at least 1 h. The lipid extraction was performed by incubating samples
with 1.25 mL of chloroform for 1 h, followed by addition of 1.25 mL of water and incubation for 1 h.
The extracts were centrifuged for 10 min at 1000 rpm. The organic phase was separated and completely
dried under N2 flow.
Thin layer chromatography (TLC) was performed in two steps with hexane/diethyl ether/acetic
acid (1◦ step 60:40:10 and 2◦ step 90:10:1). After the run and plate drying, samples were stained in an
iodine atmosphere chamber. The samples of interest were scrapped from the plate. The free fatty acid
spot was quantified after extraction, as follows: 1 mL of water, 12 h of repose, addition of 10 mL of
Econo-Safe™ Biodegradable Counting Cocktail (Research Products International, Mount Prospect,
USA) and scintillation reading. The PLA2 activities were determined in counts per minute (cpm)
after 1 h of incubation (subtracting the zero time from control) [16]. Cpm were converted to DPPC
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mass based on the specific activities of the starting material and were expressed as nmol of DPPC
hydrolyzed/min/mg protein. Protein contents were measured by Coomassie blue assay, using the
Quick Start Bradford Dye reagent (BioRad, Hercules, USA).
2.5. Phosphorylation Treatments of Non-Mammalian Prdx6
The human kinase Erk2 (GI: 119554) was selected for the in vitro phosphorylation assays (Merck
14-550, Darmstadt, Germany). Each one of the non-mammalian Prdx6 (150 ng/µL) was incubated
in reaction buffer (50 mM Tris-Cl pH 7.5, 20 µM EGTA) containing 10 mM MgCl2 and 2 mM ATP in
the presence or absence (as control) of active Erk2 kinase (10 ng/µL). The reactions were incubated at
30 ◦C for 90 min with slight agitation [33] and then separated for mass spectrometry (MS) analysis
or for western blot assay as described below. The Erk2 kinase solution was previously diluted to
80 ng/µL, following the manufacturer instructions (50 mM Tris-Cl pH 7.5, 0.1 mM EGTA, with or
without 0.1 mM Na3VO4, 0.1% 2-mercaptoethanol and 1 mg/mL bovine serum albumin (BSA)).
2.6. Reduction, Alkylation and Tryptic Digestion for MS
Samples obtained from the phosphorylation assay (described above) were mixed with 100 mM
ammonium bicarbonate buffer pH 8 plus 8 M urea (1:1). Sequentially, samples were reduced with
10 µL of 10 mM dithiothreitol (DTT) for 1 h at 30 ◦C and were alkylated in the dark in an Eppendorf
ThermoMixer (Eppendorf, Hamburg, Germany) by adding 10 µL of 500 mM iodoacetamide for
30 min at 25 ◦C (final volume 140 µL). After incubation, samples were diluted with 540 µL of 100
mM ammonium bicarbonate buffer pH 8. Finally, protein digestion was started by adding 3 µL of
Trypsin Gold (Promega, Madison, USA) 40 ng/µL (protein/enzyme ratio of 50:1) for 16 h at 37 ◦C. The
reaction mixtures were neutralized with 0.1% trifluoroacetic acid and were completely dried in speed
vac. For purification, extracts were resuspended in 0.1% formic acid solution. Each sample was then
concentrated through ZipTip resin (Merck, Darmstadt, Germany) according to the manufacturer’s
protocol. Subsequently, samples were dried in speed vac and stored at −20 ◦C until use.
2.7. Evaluation of Thr Phosphorylation by MS
The resulting peptides were analyzed by liquid chromatography-tandem mass spectrometry
(LC-MS/MS) using a nanoACQUITY UPLC system (Waters Corporation, Milford, USA) coupled
to a TripleTOF 6600 mass spectrometer (AB SCIEX, Framingham, USA). Analysis was conducted
under trap and eluted mode using a nanoACQUITY UPLC-Symmetry (Waters Corporation, Milford,
USA) containing a C18 trap column (20 mm × 180µm; 5µm) and a separation column (75µm ×
150 mm; 3.5µm). Trapping was done at 10µL/min with 2% of solvent B. Peptides were separated
with mobile phase A (0.1% formic acid in water) and B (0.1% formic acid in acetonitrile) at a flow rate
of 0.4µL/min using the following gradient: 2–35% B from 0 to 60 min; 35–85% B from 60 to 61 min;
isocratic elution with 85% B from 61 to 65 min; 85–2% B from 65 to 66 min; isocratic elution with 2% B
from 66 to 85 min. Nano-electrospray ion source was operated at 2.2 kV (ion spray voltage floating,
ISVF), curtain gas 20, interface heater (IHT) 120, ion source gas 1 (GS1) 3, ion source gas 2 (GS2) zero,
declustering potential (DP) 80 V. Time-of-flight mass spectrometry (TOF-MS) and mass spectrometry
analyzis (MS/MS) data were acquired using information-dependent acquisition (IDA) mode. For IDA
parameters, a 250 ms survey scan in the m/z (mass-to-charge ratio) range of 300–2000 was followed by
25 MS/MS ions in the m/z range of 100–2000 acquired with an accumulation time of 100 ms (total cycle
time 2.8 s). Switch criteria included, intensity greater than 150 counts and charge state 2–5. Former
target ions were excluded for 4 s. Software used for acquisition and data processing were Analyst®TF
1.7 (AB SCIEX, Framingham, USA) and PeakView®2.2 (AB SCIEX, Framingham, USA), respectively.
For the analysis of protein modification, MASCOT 2.4 software (Matrix Science Ltd., London, United
Kingdom, Redoxoma-FAPESP user license 10.10.1.46/Mascot) was used with mass tolerance of 10 ppm
for MS experiments and 0.05 Da for MS/MS experiments.
Antioxidants 2019, 8, 52 6 of 17
2.8. Evaluation of Prdx Phosphorylation by Western Blot
After the phosphorylation reaction, samples (10 µL) were reduced using DTT (100 mM), then
heated (95 ◦C) for 5 min and analysed by SDS-PAGE (12%) (50 min/200 V). The gel was transferred to
nitrocellulose membranes using NuPAGE®transfer buffer (Thermo Fisher Scientific NP0006, Waltham,
US) (90 min/35 V). Ponceau S staining was used to verify the total protein amount. The blocking
step was performed with buffer Odyssey (Li-Cor Biosciences 927-40000, Nebraska, USA) at room
temperature for 90 min. The membrane was incubated with anti-phosphorylated Prdx6 primary
antibody (anti-mouse P-Prdx6 S3091-1, Covance Research Products, Denver, USA) [17], diluted
1:200 in a mix with block buffer: TBS-T (1:4), overnight at 4 ◦C. TBS-T was used to wash the
membrane (3 × 10 min). The incubation with secondary antibody anti-rabbit IRDye® 800CW (Li-Cor
Biosciences 925-32211, Nebraska, USA), diluted 1:5000 in TBS-T, was performed for 45 min at room
temperature. The antibody to phosphorylated Prdx6 was generated by Proteintech (Chicago, USA)
using a phosphorylated mouse Prdx6 peptide (TGTKPVApTPVDWKKG) that contains the Thr 177
and has been described and validated previously [17].
3. Results
3.1. Conservation of PLA2 Catalytic Triad in Non-Mammalian Prdx6
Comparing the sequences of Prdx6 from different organisms, we observed that the peroxidase
motif (PVCTTE) (Figure 1, light red) and the corresponding catalytic triad (Figure 1, dark red) are fully
conserved, with the exception of one single replacement of amino acid with similar physico-chemical
properties in Prdx6 from Selaginella moellendorffii (PVCTSE).
In contrast, the PLA2 motif (Figure 1) is not as conserved among Prdx6 enzymes as the peroxidase
motif. The conserved His (His26 in human Prdx6) is present in most sequences (Figure 1, dark green),
with few exceptions: a change to Tyr in Plasmodium falciparum, Drosophila melanogaster and Saccharomyces
cerevisiae sequences or a change to Asp in the archaeal proteins from Aeropyrum pernix and Pyrococcus
horikoshii (Figure 1, dark green). Likewise, Ser (Ser32 in human Prdx6) is conserved in many sequences,
presenting a change to Gly in Triticum aestivum, Azotobacter vinelandii and the archaeal proteins, or to
Gln or Asn in Caenorhabditis elegans and Neurospora crassa, respectively.
Finally, the last residue of the PLA2 triad, Asp (Asp140 in human Prdx6) is present in almost all
sequences, with the exception of P. falciparum Prdx6, in which a Glu appears, maintaining the acidic
properties. Notably, this conserved residue Asp may be located at two slightly distinct positions:
in archaea, bacteria and fungus taxa, it is two amino acids backwards compared to other sequences
(Figure 1, dark green). Possibly, this conserved Asp occupies similar position in the tertiary structure
among distinct Prdx6 enzymes, keeping its function in catalysis.
The Thr residue (Thr177 in human Prdx6) that is subjected to phosphorylation in mammalian
enzymes is highly conserved in almost all analyzed sequences. The exceptions are the archaeal ones
(Figure 1, gray). It is worth mentioning that the Thr from AfPrx1 is one position backward compared
to the other sequences. Although this Thr residue is highly conserved, the surrounding amino acid
sequences are quite distinct among non-mammalian Prdx6 enzymes, especially in AfPrx1 and AfPrxC.
In contrast, the lysosomal target sequence exhibits higher variability among Prdx6 enzymes
(Figure 1, light green). Notably, the last 5 residues are highly conserved among the analyzed sequences
(Leu-Phe/Leu-Ser-His-Pro) (LF/LSHP) (Figure 2). Considering the structural characteristics indicated
above, we decided to investigate if other Prdx6 enzymes from non-mammalian organisms display
PLA2 activity.
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Figure 1. Alignment of representative Peroxiredoxins class 6 (Prdx6) enzymes from organisms that
belong to diverse phylogenetic groups. Lysosomal putative target sequence (light green), phospholipase
A2 (PLA2) catalytic triad (dark green), Prdx6 peroxidase motif (light red), peroxidatic catalytic triad
(dark red) and the Thr that is putatively subjected to phosphorylation (gray) are highlighted.
Antioxidants 2019, 8, 52 8 of 17Antioxidants 2018, 7, x FOR PEER REVIEW  8 of 17 
 
Figure 2. Graphical representation of residue conservation in the putative lysosomal target sequence. 
The letter size represents the conservation of each residue, while their color represents the chemical 
property of the corresponding amino acid. Polar amino acids Gly (G), Ser (S), Thr (T), Tyr (Y), Cys (C) 
are depicted in green; neutral amino acids Gln (Q) and Asn (N) are in magenta; basic amino acids 
Leu (L), Arg (R), His (H) are in blue; acidic amino acids Asp (D) and Glu (E) are in red; hydrophobic 
amino acids Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Trp (W), Phe (F), Met (M) are in black. The logo 
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Asp residues in the amino acid sequences are reflected in the predicted three-dimensional 
structures: (1) the plant orthologues and the human Prdx6 have the Asp in a similar position, 
whereas (2) the orthologues from fungi and bacteria have the conserved Asp in a backward position 
(Figure 4). The main difference between non-mammalian Prdx6 and human orthologues is the Ser 
-->Gly substitution observed in TaPER1 (Figure 4). The structural similarities among these proteins 
suggest that they can display PLA2 activity. 
Figure 2. Graphical representation of residue conservation in the putative lysosomal target sequence.
The letter size represents the conservation of each residue, while their color represents the chemical
property of the corresponding amino acid. Polar amino acids Gly (G), Ser (S), Thr (T), Tyr (Y), ys
(C) are depicted in green; neutral amino acids Gln (Q) and Asn (N) are in magenta; basic amino acids
Leu (L), Arg (R), His (H) are in blue; acidic amino acids Asp (D) and Glu (E) are in red; hydrophobic
amino acids Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Trp (W), Phe (F), Met (M) are in black. The logo
was generated with the WebLogo application (http://weblogo.berkeley.edu).
3.2. Structural Conservation of Prdx6 Motifs in TaPER1, AtPER1, AfPrx1, AfPrxC, and PaLsfA
Next, we investigated the three-dimensional conservation of the PLA2 catalytic triad by modeling
the structures of TaPER1, AtPER1, AfPrx1, AfPrxC, and PaLsfA. The PLA2 and the peroxidatic active
sites are conserved and are located at opposite sides of their thioredoxin fold (Figure 3), as previously
described for mammalian Prdx6 [34]. Apparently, in all the predicted structures, the putative substrate
(a phospholipid) for the PLA2 activity would fit in the corresponding cavity (Figure 3). Remarkably,
the two distinct positions occupied by the conserved Asp residues in the amino acid sequences are
reflected in the predicted three-dimensional structures: (1) the plant orthologues and the human Prdx6
have the Asp in a similar position, whereas (2) the orthologues from fungi and bacteria have the
conserved Asp in a backward position (Figure 4). The main difference between non-mammalian Prdx6
and human orthologues is the Ser –>Gly substitution observed in TaPER1 (Figure 4). The structural
similarities among these proteins suggest that they can display PLA2 activity.
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3.3. Acidic, Ca2+-Independent PLA2 (aiPLA2) Activity of Non-Mammalian Prdx6
Next, we evaluate the PLA2 activity of four (4) non-mammalian enzymes. All of the analyzed
proteins displayed PLA2 activity at acidic conditions (pH 4) in a Ca2+-independent manner (Table 1),
consistent with the so-called acidic Ca2+-independent phospholipase A2 (aiPLA2) described before
for the human Prdx6 [34]. In addition, these activities attained similar values, ranging from 3.38 for
PaLsfA to 6.09 for AfPrx1 nmol/min/mg protein (Table 1).
Table 1. PLA2 specific activity (nmol/min/mg protein) for non-mammalian Prdx6 at different pHs.
Organism
Protein Activity (nmol/ in/mg prot.)
pH 4 pH 7
T. aestivum TaPER1 4.46 ± 0.1 0.06 ± 0.01
A. fumigatus AfPrx1 6.09 ± 0.1 0.7 ± 0.2
AfPrxC 4.91 ± 0.2 0.5 ± 0.1
P. aeruginosa PaLsfA 3.38 ± 0.1 0.04 ± 0.002
3.4. Phosphorylation at the C-terminal Thr Is Also Conserved Among Non-Mammalian Prdx6
Thr177 phosphorylation of human Prdx6 increases its PLA2 activity, especially at neutral
pH [15]. Therefore, we investigated if human Erk2 could phosphorylate homologous Thr residues in
non-mammalian Prdx6 proteins. Several phosphorylation sites were found in the two plant proteins
(TaPER1 and AtPER1) and also in the mitochondrial Prdx6 from A. fumigatus (AfPrxC) (data not
shown), including the Thr homologous of human Prdx6 Thr177. However, only TaPER1 presented an
elevated score (Figure S1). In contrast, AfPrx1 and PaLsfA proteins were not phosphorylated as no
phosphorylated peptide was found for either protein by mass spectrometry (Table 2).
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Table 2. MS/MS analysis of 1-Cys Prdx purified proteins after human Erk2 treatment and digestion. Only the peptides containing the Thr homologous to Thr177 of
human Prdx6 are shown. The presence of phosphorylation is indicated in red (+Phospho).
Organism Protein Fragment Detected after Digestion Observed Mass Charge Score Error (ppm)
T. aestivum TaPER1
HKVAT(+Phospho)PANWNPGECVVIAPGVSDDEAKK 768.11 4 61 5.53
HKVATPANWNPGECVVIAPGVSDDEAKK 748.12 4 85 4.89
A. thaliana AtPER1
ALDSLLMASKHNNKIAT(+Phospho)PVNWKPDQPVVISPAVSDEEAK 859.43 5 31 5.77
ALDSLLMASKHNNKIATPVNWKPDQPVVISPAVSDEEAK 843.44 5 29 2.38
A. fumigatus
AfPrx1
VVDALQTTDKHGVTCPINWLPGDDVIIPPPVSTEDAK 1000.25 4 42 5.96
VVDALQTTDKHGVTCPINWLPGDDVIIPPPVSTEDAK 1000.26 4 50 2.06
AfPrxC
VIDALQAADKKGIAT(+Phospho)PIDWTVGEDVIVPPSVSTEDAK 983.00 4 19 0.31
VIDALQAADKKGIATPIDWTVGEDVIVPPSVSTEDAK 963.01 4 56 2.35
P. aeruginosa PaLsfA
VIDSLQLTDEHKVATPANWEDGDEVVIVPSLKDEEEIKR 1473.07 3 111 8.59
VIDSLQLTDEHKVATPANWEDGDEVVIVPSLKDEEEIKR 1473.07 3 65 7.64
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We also verified the possible Thr phosphorylation of AfPrx1 and AfPrxC by western blot using
an antibody developed to detect phosphorylated Thr residues in mouse Prdx6 [17]. A band for
phosphorylated protein was only observed for AfPrxC (Figure 5), similar to the mass spectrometry
results (Table 2).
  
Antioxidants 2018, 7, x; doi: FOR PEER REVIEW  www.mdpi.com/journal/antioxidants 
We also verified the possible Thr phosphorylation of AfPrx1 and AfPrxC by western blot using 
an antibody developed to detect phosphorylated Thr residues in mouse Prdx6 [17]. A band for 
phosphorylated protein was only observed for AfPrxC (Figure 5), similar to the mass spectrometry 
results (Table 2). 
65	
30	
25	
17	
M 	
A fPrx1	 A fPrxC	
N T	 PT	 N T	 PT	M 	
A fPrx1	 A fPrxC	
N T	 PT	 N T	PT	
 
Figure 5. Evaluation of AfPrx1 and AfPrxC phosphorylation. Left panel represents the membrane 
stained with Ponceau S as the loading control. Right panel represents the Western Blot using the 
primary antibody for phosphorylated MmPrdx6. Lane 1: molecular ladder, the numbers at the left 
side represent the molecular weight (kDa); lane 2: non-treated (NT) AfPrx1; lane 3: AfPrx1 after 
phosphorylation treatment (PT); lane 4: non-treated AfPrxC; lane 5: AfPrxC after phosphorylation 
treatment. The lower bands represent the Prdx and upper bands represent the kinase Erk2. 
Phosphorylation treatment is described in the Material and Methods section. 
3.5. Influence of Phosphorylation and Inhibition with MJ33 on PLA2 Activity of AfPrx1 and AfPrxC 
Then, the effects of the phosphorylation treatment on the PLA2 activity were determined for 
AfPrx1 and AfPrxC. Both proteins had their activities increased almost four (4) times after treatment 
with human Erk2 (Table 3). Next, we evaluated if MJ33, a classical competitive inhibitor of 
mammalian Prdx6, could inhibit the fungal Prdxs [7]. MJ33 inhibited about 85% of the aiPLA2 
activities of AfPrx1 and AfPrxC. 
Table 3. PLA2 specific activity (nmol/min/mg protein) for non-mammalian Prdx6 in different pH, 
phosphorylation treatment with Erk2 and after inhibition with 
1-hexadecyl-3-trifluoro-ethylglycero-sn-2-phosphomethanol (MJ33). ND: non-determined. 
Treatment AfPrx1 AfPrxC 
pH 4 pH 7 pH 4 pH 7 
No treatment 6.09 ± 0.1 0.7 ± 0.2 4.91 ± 0.2 0.5 ± 0.1 
Erk2 21.85 ± 0.5 20.96 ± 0.3 18.69 ± 0.2 18.47 ± 0.1 
MJ33 0.85 ± 0.05 ND 0.89 ± 0.01 ND 
4. Discussion 
The aiPLA2 activity of mammalian Prdx6 was first detected in 1992 in isolated rat lungs [35] and 
then in epithelial cell cultures [36]. The protein was identified, cloned and enzymatically 
characterized as a lysosomal type, Ca2+-independent PLA2 [7]. Shortly after that, the Cys-based 
peroxidase activity of human Prdx6 was described. Then, it was realized that these aiPLA2 and the 
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stained ith Ponceau S as the loading control. Right panel represents the Western Blot using the primary
antibody for phosphorylated MmPrdx6. Lane 1: molecular ladder, the numbers at the left side represent
the molecular weight (kDa); lane 2: non-treated (NT) AfPrx1; lane 3: AfPrx1 after phosphorylation
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bands represent the Prdx and upper bands represent the kinase Erk2. Phosphorylation treatment is
described in the Material and Methods section.
3.5. Influence of Phosphorylation and Inhibition with MJ33 on PLA2 Activity of AfPrx1 and AfPrxC
Then, the effects of the phosphorylation treatment on the PLA2 activity were determined for
AfPrx1 and AfPrxC. Both proteins had their activities increased almost four (4) times after treatment
with human Erk2 (Table 3). Next, we evaluated if MJ33, a classical competitive inhibitor of mammalian
Prdx6, could inhibit the fungal Prdxs [7]. MJ33 inhibited about 85% of the aiPLA2 activities of AfPrx1
and AfPrxC.
Table 3. PLA2 specific activity (nmol/min/mg protein) for non-mammalian Prdx6 in different pH,
phosphorylation treatment with Erk2 and after inhibition with 1-hexadecyl-3-trifluoro-ethylglycero-
sn-2-phosphomethanol (MJ33). ND: non-determined.
Treatment
AfPrx1 AfPrxC
pH 4 pH 7 pH 4 pH 7
No treatment 6.09 ± 0.1 0.7 ± 0.2 4.91 ± 0.2 0.5 ± 0.1
Erk2 21.85 ± 0.5 20.96 ± 0.3 18.69 ± 0.2 18.47 ± 0.1
MJ33 0.85 ± 0.0 ND 0.89 ± 0.01 ND
4. Discussion
The aiPLA2 activity of mammalian Prdx6 was first detected in 1992 in isolated rat lungs [35] and
then in epithelial cell cultures [36]. The protein was identified, cloned and enzymatically characterized
as a lysosomal type, Ca2+-independent PLA2 [7]. Shortly after that, the Cys-based peroxidase activity
of human Prdx6 was described. Then, it was realized that these aiPLA2 and the human Prdx6
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enzymes shared the same amino acid sequence [7]. Therefore, Prdx6 is a bi-functional enzyme with
Cys-based peroxidase and aiPLA2 activities. Later, the biological relevance of this aiPLA2 activity
was demonstrated, that is, phospholipid turnover, repair of cell membranes;, and NADPH oxidase 2
(NOX2) activation [16,17,37].
Intriguingly, aiPLA2 activity had not yet been evaluated in non-mammalian Prdx6 proteins
before this work. Here, we observed that five non-mammalian Prdx6 displayed conserved amino
acid sequenced and structural features (Figures 1–4) compatible with enzymes endowed with aiPLA2
activities. Indeed, the overall structures modeled here were very similar to the human Prdx6. In all
cases, accessible active sites were present and the conserved catalytic triads were in the expected
position. In mammalian Prdx6, it is proposed that the peroxidized sn-2 acyl phospholipid chain enters
into the pocket, where the peroxidatic Cys is located on the bottom, and the PLA2 active site is on
the top. Therefore, Prdx6 can reduce and hydrolyze the peroxidized phospholipid [38]. Next, we will
consider how each specific featured related to PLA2 activity is conserved among non-mammalian
Prdx6 enzymes.
In human Prdx6, His26 is postulated to play roles in phospholipid binding, as the positive charge
of this residue can interact with the negative charge of the substrate [12]. In some Prdx6 sequences, a
Tyr residue replaces this conserved His (proteins from P. falciparum, D. melanogaster and S. cerevisiae).
We did not investigate any of these enzymes here.
Ser32 of human Prdx6 is also important for the interaction of the enzyme with the substrate
and for stabilization of protein structure [12]. Almost 70% of the analyzed sequences possess this
residue conserved. However, four homologs, including the TaPER1, possess Gly in the same position.
Nevertheless, TaPER1 displayed PLA2 activity at similar levels to the other Prdx6 analyzed in the
present work. Notably, the mutation of catalytic Ser to Asn, Thr, Ala or Asp in human lipoprotein
lipase (LPL) abolished the enzymatic activity but when this same Ser residue was mutated to Gly,
the activity was maintained [39].
Asp140 of human Prdx6 plays a central role in PLA2 catalysis [12] and is the most conserved
residue of the catalytic triad. Indeed, the conserved Asp is replaced in only one case (from P. falciparum)
by Glu, which is also a negatively charged residue. Notably, the conserved Asp residue can be located
at two distinct positions. The proteins analyzed here possess this conserved Asp residue in either
one of the two positions (Figure 1; Figure 4) and all of them displayed similar PLA2 activity (Table 1).
Therefore, it is reasonable to assume that these differences in the Asp positioning do not interfere with
PLA2 activity.
Thr177 of recombinant human Prdx6 when phosphorylated caused a 30-fold increase in
PLA2 activity [40] and is conserved in all sequences, excluding the archaeal proteins. Therefore,
we investigated if non-mammalian Prdx6 enzymes could be phosphorylated by human Erk2. Three
(TaPER1, AtPER1, AfPrxC) out of the five non-mammalian Prdx6 were phosphorylated at the conserved
Thr residue (Table 2). Possibly, this conserved Thr of TaPER1, AtPER1, AfPrxC is phosphorylated
by plant and fungal kinases, which could increase their PLA2 activity. Indeed, AfPrxC treated with
human Erk2 had a four-fold increase in its activity (Table 3). Although, we have no experimental
evidence that PaLsfA and AfPrx1 are phosphorylated, we cannot exclude the possibility that these
peroxidases undergo this post-translational modification in vivo. It is possible that native kinases in
P. aeruginosa and A. fumigatus might phosphorylate these Prdx6 enzymes.
The investigation of the physiological meaning of PLA2 activity in Prdx6 enzymes is complex as
these proteins also display peroxidase activity. Indeed, participation of PLA2 activities of mammalian
Prdx6 in distinct cellular processes were revealed several years after they were first characterized.
For instance, the human alveoli are covered by surfactant, a surface active material able to reduce
surface tension at the alveolar air-liquid interface [41]. This function prevents the alveoli from
collapsing at end-respiration [42]. Pulmonary surfactant is composed of approximately 90% lipids
and 10% protein and the major component of surfactant is the amphiphatic phospholipid DPPC
(around 40% total) [43]. This layer is subjected to constant remodeling and the mammalian Prdx6 are
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important in this process of recycling in lamelar bodies (acid organelles) [13,16,17]. Since A. fumigatus
and P. aeruginosa colonize the lungs, starting from alveoli, it is reasonable to speculate that the PLA2
activity of these proteins (AfPrx1, AfPrxC and PaLsfA) might contribute to the colonization process
favoring the lung tissue invasion and colonization.
Accordingly, several phospholipases produced by pathogenic bacteria and fungus are virulence
factors [44,45]. In P. aeruginosa, for example, ExoU is injected directly into the cytoplasm of host cells
through the type III secretion system [46] and rapidly destroys the cell membranes of mammalian cells
by its PLA2 activity [47]. The presence of ExoU is associated with antibiotic resistance and the severe
outcome of many infections [48].
During the infection of mammalian hosts, phospholipase enzymes released by fungi can play
important roles in tissue invasion and nutrient acquisition [49,50]. In A. fumigatus, two phospholipase
B (plb) genes (Afplb1 and Afplb2) encode two secreted PLB and are upregulated in the presence of the
major component of lung surfactant (DPPC) [44,50], substrate analyzed as substrate in the present
work. Interestingly, the AfPrx1 was detected in the secretoma of A. fumigatus [51] and can cleave DPPC
in the sn-2 position (present work).
In plants, PLAs are involved in a wide range of cellular processes, including pollen and seed
development, protection against water loss and also during jasmonic acid production, a compound
related to signaling during plant defenses to distinct stressful conditions [51]. Interesting, HvPER1
(from Hordeum vulgares) and AtPER1 are highly expressed and accumulated in nucleus from embryos,
especially during the final step of seed development, the desiccation step [22,52]. At this stage,
the elevated production of reactive oxygen species is associated to the extreme loss of water along with
the reduction in metabolism and antioxidant enzymatic defenses [53,54].
5. Conclusions
This is the first description of PLA2 activities for non-mammalian Prdx6 enzymes. Notably,
the activity of the mammalian Prdx6 (≈ 100 nmol/min/mg protein) is about 20 times the activity
obtained for non-mammalian Prdx6 (≈ 5 nmol/min/mg protein). Possibly, the liposomes used
herein were not optimal substrates for non-mammalian Prdx6, as these lipids were designed to
mimic human pulmonary surfactants. Indeed, the investigation of the PLA2 activities for the Prdx6
enzymes represents an open field for future research as the roles of lipids in cellular signaling is
increasingly recognized.
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